CGON Stock Forecast & Price Target

CG Oncology is supported by a de-risked, multi-shot pipeline centered on cretostimogene grenadenorepvec, with encouraging clinical validation across HR BCG-unresponsive NMIBC, intermediate-risk NMIBC, and combination settings. The most important fundamental driver is the upcoming PIVOT-006 Phase 3 topline in November 2026, where management has framed roughly 0.70 RFS HR as a clinically meaningful hurdle and the company ended the quarter with $984.5 million in cash, cash equivalents, and marketable securities, expected to fund operations through 2029. Beyond that, a BLA submission completion in 4Q26, plus prior data showing 76% to 85.7% complete response rates and no Grade 3+ treatment-related adverse events, support a potential first-in-class commercial opportunity with broad market expansion.

CG Oncology is a developmental-stage biotech with nearly all value concentrated in cretostimogene, making the stock highly exposed to clinical, regulatory, and commercial setbacks in NMIBC. The lead program faces meaningful downside risk from a potential CRL on its initial BLA in HRBCG-UR CIS NMIBC, disappointing data in IR/HR NMIBC, safety signals, and delays across two phase three trials and a phase two study. Competitive pressure, especially from TAR-200, could limit market penetration and sales, while an inability to fund operations from commercial revenue may force additional fundraising and dilute shareholders.